Get started
Author

Susanne Hartz

Observed names: Hartz, Susanne, S Hartz, S. Hartz, Susanne C Hartz
ORCID: 0000-0001-8475-0260
Observed ORCID: 0000-0001-8475-0260
OpenAlex ID: A5063199784
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
2017 · K. Reich, A. Pinter, et al. · British Journal of Dermatology · 193
PDF
Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review
2007 · Susanne Hartz, Jürgen John · International Journal of Technology Assessment in Health Care · 98
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis
2020 · Adeline Ruyssen-Witrand, Richard Perry, et al. · RMD Open · 90
PDF
Public Health Policy Decisions on Medical Innovations: What Role Can Early Economic Evaluation Play?
2007 · Susanne Hartz, Jürgen John · Health Policy · 62
Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine
2008 · Wolf H Rogowski, Susanne C Hartz, et al. · BMC Health Services Research · 51
PDF
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
2012 · Susanne Hartz, Denis Getsios, et al. · BMC Neurology · 40
PDF
EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis
2016 · A. Simon Pickard, Melinda Gooderham, et al. · Journal of Medical Economics · 33
PDF
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis
2017 · Sarah Al Sawah, Shonda A. Foster, et al. · Journal of Medical Economics · 28
PDF
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
2024 · Axel Dignass, Claire Ainsworth, et al. · Advances in Therapy · 24
PDF
Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
2021 · U. Mrowietz, R.B. Warren, et al. · Journal of the European Academy of Dermatology and Venereology · 24
PDF
Evaluación de la eficiencia de los tratamientos biológicos en la psoriasis moderada a grave en España: análisis de coste por número necesario a tratar (NNT)
2019 · M. Núñez, T. Huete, et al. · Actas Dermo-Sifiliográficas · 16
Network Meta-Analysis To Evaluate The Efficacy of Ixekizumab In The Treatment of Moderate-To-Severe Psoriasis
2016 · S Hartz, S Walzer, et al. · Value in Health · 14
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
2018 · Erin Johansson, Mercedes Nuñez, et al. · ClinicoEconomics and Outcomes Research · 11
PDF
Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy
2024 · Melania Dovizio, Susanne Hartz, et al. · Advances in Therapy · 10
PDF
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK
2018 · Erin Colleen Johansson, Susanne Hartz, et al. · Journal of Medical Economics · 10
PDF
Elicitation of health state utilities associated with varying severities of flares in Systemic Lupus Erythematosus
2015 · C. Pollard, S. Hartz, et al. · Health and Quality of Life Outcomes · 10
PDF
Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn’s Disease: A Real-World Global Study
2024 · Raja Atreya, Isabel Redondo, et al. · Crohn s & Colitis 360 · 9
PDF
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
2020 · Bernd Schweikert, Chiara Malmberg, et al. · PharmacoEconomics - Open · 9
PDF
A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis
2019 · M. Núñez, T. Huete, et al. · Actas Dermo-Sifiliográficas · 8
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
2020 · Bernd Schweikert, Chiara Malmberg, et al. · BMJ Open · 7
PDF
Pmu66 - Cost-effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-to-severe Psoriasis in Spain
2018 · B Schweikert, CT Storck, et al. · Value in Health · 4
P105 Mirikizumab versus ustekinumab in moderately to severely active ulcerative colitis: maintenance number needed to treat from a network meta-analysis
2024 · Axel Dignass, Isabel Redondo, et al. · Gut · 3
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study
2023 · Axel Dignass, Isabel Redondo, et al. · Current Medical Research and Opinion · 3
PDF
P261 Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients – real world global study analyses
2022 · R Atreya, I Redondo, et al. · Journal of Crohn s and Colitis · 3
MSR180 Challenges in NMA Methodology Based on Re-Randomization vs Treat-through Trial Designs
2024 · S Petersohn, M Ho, et al. · Value in Health · 2
PDF
Works count: 42
Citation count: 773
H-index: 12
I10-index: 16
Year
Topic
Type